Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies

Alison T Stopeck, Marrae Sheldon, Mahmood Vahedian, Gillian Cropp, Rishi Gosalia, Alison Hannah

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor. In this Phase I dose escalation trial, a weekly dose schedule of SU5416 was tested whereby an initial 5-day loading dose was followed by weekly maintenance infusions. The start dose was 20 mg/m2 for the loading dose followed by 65 mg/m2 for the weekly infusions. Dose escalations occurred at 33% until a final dose of 65 mg/m2 (loading dose) and 190 mg/m2 (weekly infusion) was obtained. Twenty-two patients were treated at five dose levels; tumor types included gastrointestinal (8), breast (3), lung (4), sarcoma (2), and other (5). The most common serious drug-related toxicity was headache, often associated with nausea and vomiting. Grade 1 and 2 toxicities included headache, nausea, vomiting, asthenia, pain at the infusion site, phlebitis, change in voice, and fevers. Of 19 evaluable patients, 4 obtained clinical benefit as defined by tumor regression (1) or disease stabilization for at least 12 weeks (3). Pharmacokinetic data revealed that the weekly infusion schedule prevented the reported 50-60% induction in SU5416 clearance observed with either daily or twice weekly dosing. Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies. Our results suggest that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m2.

Original languageEnglish (US)
Pages (from-to)2798-2805
Number of pages8
JournalClinical Cancer Research
Volume8
Issue number9
StatePublished - Sep 2002

Fingerprint

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Appointments and Schedules
Nausea
Vomiting
Headache
Neoplasms
Phlebitis
Asthenia
Vascular Endothelial Growth Factor Receptor-2
Receptor Protein-Tyrosine Kinases
Drug-Related Side Effects and Adverse Reactions
Sarcoma
Breast
Fever
Pharmacokinetics
Maintenance
Urine
Pain
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. / Stopeck, Alison T; Sheldon, Marrae; Vahedian, Mahmood; Cropp, Gillian; Gosalia, Rishi; Hannah, Alison.

In: Clinical Cancer Research, Vol. 8, No. 9, 09.2002, p. 2798-2805.

Research output: Contribution to journalArticle

Stopeck, Alison T ; Sheldon, Marrae ; Vahedian, Mahmood ; Cropp, Gillian ; Gosalia, Rishi ; Hannah, Alison. / Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 9. pp. 2798-2805.
@article{de40f6c44c6a4d4496c007fb29801f15,
title = "Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies",
abstract = "SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor. In this Phase I dose escalation trial, a weekly dose schedule of SU5416 was tested whereby an initial 5-day loading dose was followed by weekly maintenance infusions. The start dose was 20 mg/m2 for the loading dose followed by 65 mg/m2 for the weekly infusions. Dose escalations occurred at 33{\%} until a final dose of 65 mg/m2 (loading dose) and 190 mg/m2 (weekly infusion) was obtained. Twenty-two patients were treated at five dose levels; tumor types included gastrointestinal (8), breast (3), lung (4), sarcoma (2), and other (5). The most common serious drug-related toxicity was headache, often associated with nausea and vomiting. Grade 1 and 2 toxicities included headache, nausea, vomiting, asthenia, pain at the infusion site, phlebitis, change in voice, and fevers. Of 19 evaluable patients, 4 obtained clinical benefit as defined by tumor regression (1) or disease stabilization for at least 12 weeks (3). Pharmacokinetic data revealed that the weekly infusion schedule prevented the reported 50-60{\%} induction in SU5416 clearance observed with either daily or twice weekly dosing. Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies. Our results suggest that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m2.",
author = "Stopeck, {Alison T} and Marrae Sheldon and Mahmood Vahedian and Gillian Cropp and Rishi Gosalia and Alison Hannah",
year = "2002",
month = "9",
language = "English (US)",
volume = "8",
pages = "2798--2805",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies

AU - Stopeck, Alison T

AU - Sheldon, Marrae

AU - Vahedian, Mahmood

AU - Cropp, Gillian

AU - Gosalia, Rishi

AU - Hannah, Alison

PY - 2002/9

Y1 - 2002/9

N2 - SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor. In this Phase I dose escalation trial, a weekly dose schedule of SU5416 was tested whereby an initial 5-day loading dose was followed by weekly maintenance infusions. The start dose was 20 mg/m2 for the loading dose followed by 65 mg/m2 for the weekly infusions. Dose escalations occurred at 33% until a final dose of 65 mg/m2 (loading dose) and 190 mg/m2 (weekly infusion) was obtained. Twenty-two patients were treated at five dose levels; tumor types included gastrointestinal (8), breast (3), lung (4), sarcoma (2), and other (5). The most common serious drug-related toxicity was headache, often associated with nausea and vomiting. Grade 1 and 2 toxicities included headache, nausea, vomiting, asthenia, pain at the infusion site, phlebitis, change in voice, and fevers. Of 19 evaluable patients, 4 obtained clinical benefit as defined by tumor regression (1) or disease stabilization for at least 12 weeks (3). Pharmacokinetic data revealed that the weekly infusion schedule prevented the reported 50-60% induction in SU5416 clearance observed with either daily or twice weekly dosing. Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies. Our results suggest that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m2.

AB - SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor. In this Phase I dose escalation trial, a weekly dose schedule of SU5416 was tested whereby an initial 5-day loading dose was followed by weekly maintenance infusions. The start dose was 20 mg/m2 for the loading dose followed by 65 mg/m2 for the weekly infusions. Dose escalations occurred at 33% until a final dose of 65 mg/m2 (loading dose) and 190 mg/m2 (weekly infusion) was obtained. Twenty-two patients were treated at five dose levels; tumor types included gastrointestinal (8), breast (3), lung (4), sarcoma (2), and other (5). The most common serious drug-related toxicity was headache, often associated with nausea and vomiting. Grade 1 and 2 toxicities included headache, nausea, vomiting, asthenia, pain at the infusion site, phlebitis, change in voice, and fevers. Of 19 evaluable patients, 4 obtained clinical benefit as defined by tumor regression (1) or disease stabilization for at least 12 weeks (3). Pharmacokinetic data revealed that the weekly infusion schedule prevented the reported 50-60% induction in SU5416 clearance observed with either daily or twice weekly dosing. Higher baseline levels of urine VEGF were observed in the 4 patients who gained clinical benefit, suggesting this may be a useful marker for predicting response to anti-VEGF therapies. Our results suggest that a weekly schedule of SU5416 shows signs of biological activity and is well tolerated at doses up to 145 mg/m2.

UR - http://www.scopus.com/inward/record.url?scp=0036718003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036718003&partnerID=8YFLogxK

M3 - Article

C2 - 12231519

AN - SCOPUS:0036718003

VL - 8

SP - 2798

EP - 2805

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -